Vistusertib (AZD2014)
Catalog No.S2783
Molecular Weight(MW): 462.54
Vistusertib (AZD2014) is a novel mTOR inhibitor with IC50 of 2.8 nM in a cell-free assay; highly selective against multiple PI3K isoforms (α/β/γ/δ). AZD2014 showed no or weak binding to the majority of kinases when tested at 1 μM.
13 Customer Reviews
-
Cell Oncol, 2018, doi:10.1007/s13402-018-0380-x. Vistusertib (AZD2014) purchased from Selleck.
Murine macrophages were treated with AZD2014 (10 nm) or rapamycin (10 ng/ml) for the time periods indicated. B, immunoblot analysis of whole cell lysate performed using an antibody detecting total ERK and phospho-ERK (Thr202/Tyr204). C, detection of MKP-1. Immunoblot analysis of whole cell lysate performed using an antibody against MKP-1 and β-actin.
J Biol Chem 2013 288(47), 33966-77. Vistusertib (AZD2014) purchased from Selleck.
-
Biochem Biophys Res Commun 2014 443(2), 406-12. Vistusertib (AZD2014) purchased from Selleck.
Biochem Biophys Res Commun 2014 443(2), 406-12. Vistusertib (AZD2014) purchased from Selleck.
-
Biochem Biophys Res Commun 2014 443(2), 406-12. Vistusertib (AZD2014) purchased from Selleck.
Biochem Biophys Res Commun 2014 443(2), 406-12. Vistusertib (AZD2014) purchased from Selleck.
-
HT-29 cells were treated with vehicle or AZD-2014 (50 nM) for 72 h, cell cycle distribution was analyzed by FACS.
Biochem Biophys Res Commun 2014 443, 406-12. Vistusertib (AZD2014) purchased from Selleck.
HT-29 cells were treated with vehicle ("Ctrl") or different concentrations of AZD-2014 for 72 h.
Biochem Biophys Res Commun 2014 443, 406-12. Vistusertib (AZD2014) purchased from Selleck.
-
Accumulation of autophagosomes in the cytoplasm after 72 h treatment with WORT, CQ, AZD2014 or TMX or their combination with DOX, was visualized after anti-LC3 antibody labeling.
Histochem Cell Biol, 2017, 148(5):529-544. Vistusertib (AZD2014) purchased from Selleck.
AZD-2014 potentiates resminostat's cytotoxicity against human HCC cells. Established HCC cell lines (HepG2, SMMC-7721 and Hep3B), primary HCC cells (two lines, "HCC-1/-2") or the HL-7702 hepatocytes were treated with resminostat (at applied concentrations) or plus AZD-2014 ("AZD", 10 nM), cells were further cultured and subjected to MTT assay (A, E and F), trypan blue staining assay (B) and proliferation assays (C and D); p-mTOR (Ser-2448) and regular mTOR expression was tested by Western blots (A, upper panel). Data represented the means of three independent experiments ± SD (Same for all figures). For each assay, n = 5 (Same for all figures). "CTRL" indicated untreated control group (Same for all figures). "Veh" indicated vehicle (0.1% DMSO) (AeD). "Rsm" indicated resminostat (E). # indicated statistically significant differences as compared to "CTRL" group. * indicated statistically significant differences as compared to "resminostat" only group.
Biochem Biophys Res Commun, 2016, 477(4):556-62. Vistusertib (AZD2014) purchased from Selleck.
-
Tumor growth inhibition studies were performed in SCID mice. Mice bearing 300 mm3 tumors were randomly divided into two groups and were treated with 5 mg/kg AZD-2014 (PO, QD x 14; n = 10, the dose was based on results from pre-experiments) or vehicle (saline, PO, QD x 14; n = 10). After AZD-2014 administration, tumor tissues were isolated and lysed, activation of Akt and mTORC1/2 was tested by Western blot.
Biochem Biophys Res Commun, 2014, 443(2): 406-12. Vistusertib (AZD2014) purchased from Selleck.
Autophagy in NCI-H460 (C, D) and NCI-H460/R (E, F) cells was assessed by fluorescence microscopy. Cells were stained with acridine orange to detect the presence of acidic autophagosomes (acridin orange shifts its fluorescence emission from green to red when found in acidic compartments). Nuclei were counterstained with Hoechst 33342 (blue). Number of autophagosomes increased in NCI-H460 cells (D) after 18 h of 250 nM ADZ2014 treatment, in comparison with untreated cells (C). NCI-H460/R cells treated with 100 nM AZD2014 for 18 h also showed increased number of autophagosomes in the cytoplasm (F) when compared to untreated cells (E).
2013 Dr. Milica Pesic from Institute for Biological Research. Vistusertib (AZD2014) purchased from Selleck.
-
The effects of SelleckChem inhibitors on sea urchin embryo development evaluated 24 h after fertilization. All compounds were added to embryos suspension 20 min after fertilization. The relative presence of late gastrula, swimming blastula, undeveloped embryos and dead embryos was compared next to untreated control embryos (A). Fertilized egg, swimming blastula and late gastrula are illustrated (B). The embryonic development was relatively synchronized in untreated control samples after 24 h (A, E). GSK690693 treatment sustained the development of embryos. Swimming blastulas kept normal motility regardless the deformities in their shape. Tipifarnib treatment induced significant toxicity due to occurrence of dead fragmented embryos. Some abnormal blastulas kept the motility. AZD2014 treatment sustained the development of embryos. Some developed gastrulas and blastulas were less motile in comparison with control (A, C). WZ811 was the least toxic compound. Significant number of gastrulas and blastulas was developed. However, their motility was considerably suppressed (A, D). In contrast to SelleckChem inhibitors, classic anticancer agent – cisplatin was extremely toxic to sea urchin embryos (A). Cisplatin killed many embryos, while a small amount of survived embryos was stopped at early phases of development: immediately after fertilization or after first and second division (A, F).
2013 Dr. Milica Pesic from Institute for Biological Research. Vistusertib (AZD2014) purchased from Selleck.
Purity & Quality Control
Choose Selective mTOR Inhibitors
Biological Activity
| Description | Vistusertib (AZD2014) is a novel mTOR inhibitor with IC50 of 2.8 nM in a cell-free assay; highly selective against multiple PI3K isoforms (α/β/γ/δ). AZD2014 showed no or weak binding to the majority of kinases when tested at 1 μM. | |||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Targets |
|
|||||||||||||||||||||||||||||||||||||
| In vitro |
AZD2014 is a close analogue of AZD8055 and a selective inhibitor of mTOR kinase. AZD2014 has greater inhibitory activity against mTORC1 compared to rapamycin: AZD2014 decreases p4EBP1 Thr37/46, inhibits the translation initiation complex and decreases overall protein synthesis while rapamycin has no effect. AZD2014 also inhibits the mTORC2 biomarkers pAKTSer473 and pNDRG1Thr346. AZD2014 has broad antiproliferative activity across multiple tumour cell lines. In particular, AZD2014 induces growth inhibition and cell death in breast cancer cell lines, including ER+ cell lines with acquired resistance to hormone therapy. [1] |
|||||||||||||||||||||||||||||||||||||
| Cell Data |
|
|||||||||||||||||||||||||||||||||||||
| In vivo | AZD2014 induces tumour growth inhibition against several xenograft models including a human primary explant model of ER+ breast cancer refractory to tamoxifen. The antitumour activity is associated with modulation of both mTORC1 and mTORC2 substrates. [1] |
Protocol
Solubility (25°C)
| In vitro | DMSO | 38 mg/mL (82.15 mM) |
|---|---|---|
| Water | Insoluble | |
| Ethanol | Insoluble | |
| In vivo | Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing. |
5mg/mL |
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Information
| Molecular Weight | 462.54 |
|---|---|
| Formula | C25H30N6O3 |
| CAS No. | 1009298-59-2 |
| Storage | powder |
| in solvent | |
| Synonyms | N/A |
Bio Calculators
Molarity Calculator
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Dilution Calculator
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Molarity Calculator
Clinical Trial Information
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01597388 | Active not recruiting | Advanced Metastatic Breast Cancer | AstraZeneca | May 8 2012 | Phase 1 |
| NCT02599714 | Active not recruiting | Advanced and Metastatic Breast Cancer | AstraZeneca | December 7 2015 | Phase 1|Phase 2 |
| NCT02831257 | Active not recruiting | Neurofibromatosis 2|Meningioma | Massachusetts General Hospital|AstraZeneca|United States Department of Defense | August 31 2016 | Phase 2 |
| NCT02640755 | Completed | Solid Malignancies | AstraZeneca|Quintiles Inc. | January 28 2016 | Phase 1 |
| NCT03166904 | Not yet recruiting | Solid Tumor | Samsung Medical Center | March 2018 | Phase 2 |
| NCT03166176 | Not yet recruiting | Solid Tumor | Samsung Medical Center | March 2018 | Phase 2 |
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Frequently Asked Questions
-
Question 1:
I am looking for a i.p. or i.v. formula of AZD2014. Any suggestion?
-
Answer:
S2783 AZD2014 can be dissolved in 5% DMSO/30% PEG 300/ddH2O at 5 mg/ml as a clear solution for I.P. use.
